Medtech's Focus on Enhancing Collaboration and Data Integrity
Nearly 70% say reducing manual processes is a key priority for working with sites
Recent findings from a benchmark report reveal that medtech clinical teams are increasingly focused on enhancing collaboration with research sites. The study shows that a significant percentage, around 68%, aim to reduce manual processes, which is critical for improving study quality (56%) and achieving better oversight (55%). These results highlight the ongoing need for leveraging technology to streamline clinical workflows, enhance communication with sites, and expedite trial processes.
Challenges in Site Management
Respondents to the survey pinpointed key challenges faced in site management, including on-time data entry, data quality, and the exchange of essential documents. Only a small fraction of medtech organizations—14% of those with revenues exceeding $1 billion and 24% of companies with lower revenues—currently have effective site collaboration tools. This indicates a substantial opportunity for the industry to improve trial efficiency and speed up study timelines.
Key Insights from the Benchmark Report
The report offers several important insights into the current landscape of medtech clinical trials:
- Manual Processes Increase Risk: A substantial reliance on manual processes (32%), coupled with the challenge of complying with global trial regulations (18%) and readiness for inspections (18%), emerged as the primary hurdles in clinical affairs for medtech companies. These areas contribute to heightened operational costs and significant delays in trials.
- Process Optimization Initiatives: To uphold clinical trial integrity, around 58% of the surveyed medtech organizations plan to prioritize data collection and cleaning over the next year. Enhancing the data collection process allows teams to focus on high-impact trial activities rather than on tedious data reconciliation.
- The Early Stages of AI and ML Adoption: An encouraging statistic indicates that nearly 72% of medtech organizations are planning to invest in the infrastructure necessary for artificial intelligence (AI) and machine learning (ML). The goal is to harmonize existing systems and standardize data, makingit more suitable for AI application.
Kevin Liang, vice president of clinical strategy at Veeva MedTech, stated, "The medtech industry is driving initiatives to advance clinical processes, site collaboration, and data quality. There are pressing economic pressures and new regulations, which make these improvements vital. This report underscores the commitment of medtech companies to ensure data integrity, enhance operational efficiency, and foster connected processes across stakeholders to deliver new technologies to patients more rapidly."
About Veeva MedTech
The 2025 Veeva MedTech Clinical Benchmark surveyed over 100 clinical professionals from medical device and diagnostics companies. This report thoroughly examines the current state of medtech clinical trials and the strategies teams are implementing to modernize their operations. Through its findings, it provides a clearer view of how the industry can evolve to meet its challenges and optimize results.
Veeva MedTech is committed to helping medical device and diagnostics companies streamline every aspect of the product development process. Their innovative applications are designed to enhance clinical, regulatory, quality, commercial, and medical operations. For more incredible insights, visit their website.
Frequently Asked Questions
What are the main priorities for medtech companies in clinical trials?
Medtech companies focus on reducing manual processes, improving study quality, and enhancing oversight while working with research sites.
What challenges do medtech companies face in site management?
Key challenges include on-time data entry, data quality, and document exchange, which hinder effective site management.
How many medtech companies have site collaboration tools?
Only 14% of medtech companies with revenues over $1 billion and 24% of those under that threshold have implemented site collaboration tools.
What initiatives are medtech companies taking regarding AI?
Many medtech companies (about 72%) are planning to invest in AI and ML infrastructure to enhance data processing and trial efficiency.
Why is data quality important in medtech?
High-quality data is essential for maintaining trial integrity, improving operational efficiency, and ensuring compliance with regulations.
